HomeAI · summaries
Storia in 2 fonti
Immunai signs $15M AI drug discovery deal with Boehringer Ingelheim
Multi-project collaboration, running through 2027, will use Immunai’s single-cell AI platform to identify T-cell dysfunction patterns in cancer and autoimmune diseases and advance new drug discovery programs
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
ynetnews.com
Immunai signs $15M AI drug discovery deal with Boehringer Ingelheim
Multi-project collaboration, running through 2027, will use Immunai’s single-cell AI platform to identify T-cell dysfunction patterns in cancer and autoimmune diseases and advance…
- ·
jpost.com
Israeli-founded AI biotech Immunai launches drug-discovery collaboration | The Jerusalem Post
The collaboration will use Immunai’s single-cell AI platform to identify T-cell targets in cancer and autoimmune diseases.